Zydus Lifesciences has received final approval from the USFDA to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day.
Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis.
Ref: https://www.bseindia.com/xml-data/corpfiling/AttachLive/5e28376a-ff6b-4d81-b523-049d8f8c439a.pdf
Disc: Invested
| Subscribe To Our Free Newsletter |
